London, April 17, 2012 - New research published in the Journal of Plastic, Reconstructive and Aesthetic Surgery suggests that the failure rate of silicone breast implants manufactured by Poly Implant Prosthèse (PIP) could be as high as 33.8%.
Patients who received PIP implants either for primary or secondary breast augmentation, between January 2000 and August 2005, were studied to determine implant failure rate and other complications. Results found that 7 to 12 years after implantation the failure rate for PIP implants is in the region of 15.9.8%.
"Previous studies have typically reported failure rates of between 2% and 5% and these estimates have been based on secondary data. In this study, all participants were scanned by ultrasound, which provides conclusive indication of rupture, rather than clinical examination which is typically used. Most previous studies were based on multiple surgeon, multiple technique, with a relatively small number of patients and shorter follow up time span," commented Mr. Jan Stanek, lead author of the study.
Concerns about the durability of PIP silicone breast implants have been expressed for several years prior to their formal withdrawal from the UK market in March 2010. Although precise details of what elements were at fault remain unclear, concerns have been raised about both the elastomer (the outer cover of the implant) and the filler gel.
In this study PIP implants were used by the plastic surgeon for both primary and secondary breast augmentation. A database of patients was constructed and each patient was offered a free consultation and referral for ultrasound scan. Chief outcome measures included secondary surgery, implant rupture rate and time to rupture.
453 patients with PIP devices were identified. Of this number, 30 had already undergone implant exchange for a variety of reasons. 180 (39.7%) could not be contacted and 19 had undergone implant removal elsewhere. Of those who could be contacted, 47 declined consultation as they had no concerns. 97 had neither clinical signs nor radiographic evidence of implant rupture and elected to remain under regular review. At the time of writing, 38 had undergone implant exchange after ultrasonographic indication of rupture.
Based on these results, if the group of non-responders had no ruptures, the overall rupture rate would be 15.9%. However, it the non-responders had the same rupture rate as those examined in the study, the overall rupture rate would be 33.8%.
Mr. Stanek indicates that all PIP implants, due to the high rupture rate and uncertainty about the nature of the silicone gel, may need to be removed. Those patients with ruptured implants will have to have them removed; those with no evidence of rupture will need to be monitored on a regular basis. Further research into the nature of the elastomer and gel filler will determine whether all PIP implants should be explanted in the future.
Notes for editors
This article is "The PIP mammary prosthesis: A product recall study" M.G. Berry and Jan J. Stanek (DOI: 10.1016/j.bjps.2012.02.019); in press, ahead of print in Journal of Plastic, Reconstructive and Aesthetic Surgery, published by Elsevier.
Full text of the article is freely available at www.jprasurg.com. Journalists wishing to interview the authors may contact Mr. Jan J. Stanek through Anika Keynes at +44 20 7018 1649 or anika@tohpr.com
About Journal of Plastic, Reconstructive and Aesthetic Surgery
Journal of Plastic, Reconstructive and Aesthetic Surgery (JPRAS) is the official journal of the British Association of Plastic, Reconstructive and Aesthetic Surgeons (BAPRAS) www.bapras.org.uk and is affiliated to the European Association of Plastic Surgeons (www.euraps.org).
It is one of the leading international journals in the field, covering all the reconstructive and aesthetic aspects of plastic surgery. The journal presents the latest surgical procedures with audit and outcome studies of new and established techniques in plastic surgery including: cleft lip and palate and other heads and neck surgery, hand surgery, lower limb trauma, burns, skin cancer, breast surgery and aesthetic surgery.
The journal has up-to-date papers, comprehensive review articles, letters to the editor and book reviews on all aspects of plastic surgery and related basic sciences.
About Elsevier
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include SciVerse ScienceDirect, SciVerse Scopus, Reaxys, MD Consult and Mosby's Nursing Suite, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai's Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
Media contact
Sacha Boucherie
Elsevier
+31 20 485 3564
s.boucherie@elsevier.com